In addition to unsatisfactory outcomes of single IGF-1R inhibitory agents in several clinical trials, a combination of monoclonal anti-IGF1R antibody MK-0646 [86] and IMC-A12 [87] with epidermal growth factor receptor inhibitor cetuximab was not found to improve the prognosis of patients with advanced CRC. The gene discussed is IGF1R; the disease is colorectal carcinoma.